Meenakshi Banerjee1, Yunjie Huang2, Smita Joshi1,3, Gabriel J Popa1, Michael D Mendenhall1, Qing Jun Wang4, Beth A Garvy5, Thein Myint6, Sidney W Whiteheart1,3. 1. Department of Molecular and Cellular Biochemistry (M.B., S.J., G.J.P., M.D.M., S.W.W.), University of Kentucky, Lexington. 2. Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, OH (Y.H.). 3. Lexington VA Health Care System, KY (S.J., S.W.W.). 4. Department of Ophthalmology and Visual Sciences (Q.J.W.), University of Kentucky, Lexington. 5. Department of Microbiology, Immunology and Molecular Genetics (B.A.G.), University of Kentucky, Lexington. 6. Department of Infectious Diseases, Bluegrass Care Clinic, Kentucky Clinic (T.M.), University of Kentucky, Lexington.
Abstract
OBJECTIVE: Thrombocytopenia is associated with many viral infections suggesting virions interact with and affect platelets. Consistently, viral particles are seen inside platelets, and platelet activation markers are detected in viremic patients. In this article, we sought mechanistic insights into these virion/platelet interactions by examining how platelets endocytose, traffic, and are activated by a model virion. Approach and Results: Using fluorescently tagged HIV-1 pseudovirions, 3-dimensional structured illumination microscopy, and transgenic mouse models, we probed the interactions between platelets and virions. Mouse platelets used known endocytic machinery, that is, dynamin, VAMP (vesicle-associated membrane protein)-3, and Arf6 (ADP-ribosylation factor 6), to take up and traffic HIV-1 pseudovirions. Endocytosed HIV-1 pseudovirions trafficked through early (Rab4+) and late endosomes (Rab7+), and then to an LC3+ (microtubule-associated protein 1A/1B-light chain 3) compartment. Incubation with virions induced IRAK4 (interleukin 1 receptor-associated kinase 4), Akt (protein kinase B), and IKK (IκB kinase) activation, granule secretion, and platelet-leukocyte aggregate formation. This activation required TLRs (Toll-like receptors) and MyD88 (myeloid differentiation primary response protein 88) but was less extensive and slower than activation with thrombin. In vivo, HIV-1 pseudovirions injection led to virion uptake and platelet activation, as measured by IKK activation, platelet-leukocyte aggregate formation, and mild thrombocytopenia. All were decreased in VAMP-3-/- and, megakaryocyte/platelet-specific, Arf6-/- mice. Similar platelet activation profiles (increased platelet-leukocyte aggregates, plasma platelet factor 4, and phospho-IκBα) were detected in newly diagnosed and antiretroviral therapy-controlled HIV-1+ patients. CONCLUSIONS: Collectively, our data provide mechanistic insights into the cell biology of how platelets endocytose and process virions. We propose a mechanism by which platelets sample the circulation and respond to potential pathogens that they take up.
OBJECTIVE:Thrombocytopenia is associated with many viral infections suggesting virions interact with and affect platelets. Consistently, viral particles are seen inside platelets, and platelet activation markers are detected in viremic patients. In this article, we sought mechanistic insights into these virion/platelet interactions by examining how platelets endocytose, traffic, and are activated by a model virion. Approach and Results: Using fluorescently tagged HIV-1 pseudovirions, 3-dimensional structured illumination microscopy, and transgenicmouse models, we probed the interactions between platelets and virions. Mouse platelets used known endocytic machinery, that is, dynamin, VAMP (vesicle-associated membrane protein)-3, and Arf6 (ADP-ribosylation factor 6), to take up and traffic HIV-1 pseudovirions. Endocytosed HIV-1 pseudovirions trafficked through early (Rab4+) and late endosomes (Rab7+), and then to an LC3+ (microtubule-associated protein 1A/1B-light chain 3) compartment. Incubation with virions induced IRAK4 (interleukin 1 receptor-associated kinase 4), Akt (protein kinase B), and IKK (IκB kinase) activation, granule secretion, and platelet-leukocyte aggregate formation. This activation required TLRs (Toll-like receptors) and MyD88 (myeloid differentiation primary response protein 88) but was less extensive and slower than activation with thrombin. In vivo, HIV-1 pseudovirions injection led to virion uptake and platelet activation, as measured by IKK activation, platelet-leukocyte aggregate formation, and mild thrombocytopenia. All were decreased in VAMP-3-/- and, megakaryocyte/platelet-specific, Arf6-/- mice. Similar platelet activation profiles (increased platelet-leukocyte aggregates, plasma platelet factor 4, and phospho-IκBα) were detected in newly diagnosed and antiretroviral therapy-controlled HIV-1+ patients. CONCLUSIONS: Collectively, our data provide mechanistic insights into the cell biology of how platelets endocytose and process virions. We propose a mechanism by which platelets sample the circulation and respond to potential pathogens that they take up.
Authors: Milka Koupenova; Olga Vitseva; Christopher R MacKay; Lea M Beaulieu; Emelia J Benjamin; Eric Mick; Evelyn A Kurt-Jones; Katya Ravid; Jane E Freedman Journal: Blood Date: 2014-04-22 Impact factor: 22.113
Authors: Bradlee L Heckmann; Emilio Boada-Romero; Larissa D Cunha; Joelle Magne; Douglas R Green Journal: J Mol Biol Date: 2017-08-25 Impact factor: 5.469
Authors: Zubair A Karim; Jinchao Zhang; Meenakshi Banerjee; Michael C Chicka; Rania Al Hawas; Tara R Hamilton; Paul A Roche; Sidney W Whiteheart Journal: Blood Date: 2013-04-23 Impact factor: 22.113
Authors: Soumya Panigrahi; Yi Ma; Li Hong; Detao Gao; Xiaoxia Z West; Robert G Salomon; Tatiana V Byzova; Eugene A Podrez Journal: Circ Res Date: 2012-10-15 Impact factor: 17.367
Authors: Jennifer M Lund; Lena Alexopoulou; Ayuko Sato; Margaret Karow; Niels C Adams; Nicholas W Gale; Akiko Iwasaki; Richard A Flavell Journal: Proc Natl Acad Sci U S A Date: 2004-03-19 Impact factor: 11.205